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Abstract
The objective of the present study was to identify disturbances of nitric
oxide radical (NO) metabolism and the formation of cholesterol
oxidation products in human essential hypertension. The concentra-
tions of NO derivatives (nitrite, nitrate, S-nitrosothiols and nitroty-
rosine), water and lipid-soluble antioxidants and cholesterol oxides
were measured in plasma of 11 patients with mild essential hyperten-
sion (H: 57.8 ± 9.7 years; blood pressure, 148.3 ± 24.8/90.8 ± 10.2
mmHg) and in 11 healthy subjects (N: 48.4 ± 7.0 years; blood pressure,
119.4 ± 9.4/75.0 ± 8.0 mmHg). Nitrite, nitrate and S-nitrosothiols were
measured by chemiluminescence and nitrotyrosine was determined by
ELISA. Antioxidants were determined by reverse-phase HPLC and
cholesterol oxides by gas chromatography. Hypertensive patients had
reduced endothelium-dependent vasodilation in response to reactive
hyperemia (H: 9.3 and N: 15.1% increase of diameter 90 s after
hyperemia), and lower levels of ascorbate (H: 29.2 ± 26.0, N: 54.2 ±
24.9 µM), urate (H: 108.5 ± 18.9, N: 156.4 ± 26.3 µM), ß-carotene (H:
1.1 ± 0.8, N: 2.5 ± 1.2 nmol/mg cholesterol), and lycopene (H: 0.4 ±
0.2, N: 0.7 ± 0.2 nmol/mg cholesterol), in plasma, compared to
normotensive subjects. The content of 7-ketocholesterol, 5-
cholestane-3ß,5,6ß-triol and 5,6-epoxy-5-cholestan-3-ol in LDL,
and the concentration of endothelin-1 (H: 0.9 ± 0.2, N: 0.7 ± 0.1 ng/ml)
in plasma were increased in hypertensive patients. No differences
were found for NO derivatives between groups. These data suggest
that an increase in cholesterol oxidation is associated with endotheli-
um dysfunction in essential hypertension and oxidative stress, al-
though NO metabolite levels in plasma are not modified in the
presence of elevated cholesterol oxides.
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Introduction
Endothelial cells release both relaxing
and contracting factors which participate in
the pathophysiology of essential hyperten-
sion. Nitric oxide is a free radical (NO) that
is considered to be the major endothelium-
derived relaxing factor, and is released from
endothelial cells in response to shear stress
or to the stimulation of several receptors on
the endothelial cell surface (1). Endotheli-
um-derived contracting factors include en-
dothelin-1, vasoconstrictor prostanoids, an-
giotensin II and superoxide radical (O2
-). In
patients with essential hypertension, the re-
sponse to endothelium-dependent agonists
is blunted when compared with healthy con-
trols (2). Blockade of cyclooxygenase in
hypertensive patients can restore the NO
production, suggesting that NO inactivation
may be caused by cyclooxygenase deriva-
tives (3). As O2
- is produced by cyclooxy-
genase (4), and NO rapidly reacts with O2
-
to form oxidant and nitrating species (5,6),
this NO inactivation pathway could be in-
volved in the reduction of endothelium-
dependent vasorelaxation found in patients
with essential hypertension. Nitrotyrosine
has been considered to be an end product of
tyrosine nitration induced by peroxynitrite
and other nitrating systems (6). Moreover,
nitrotyrosine has been detected in human
atherosclerotic plaques (7) and in tissues of
hypertensive rats (8).
The involvement of lipid peroxidation
during the pathogenesis of hypertension has
not been extensively studied. Cholesterol
oxides (ChOx) are formed as the result of
cholesterol oxidation catalyzed by enzymes
and by free radical-mediated reactions. ChOx
are toxic to endothelial cells (9) and inhibit
NO production by these cells (10). Oxidized
LDL (ox-LDL), containing an increased con-
tent of ChOx, reduces the endothelium-de-
pendent relaxation of isolated human inter-
nal mammary artery and rat thoracic aorta
(11). Accordingly, a number of in vitro and
ex vivo animal studies have shown that anti-
oxidants may improve endothelium-depend-
ent vasodilation by limiting lipid peroxida-
tion and improving the bioactivity of NO
(12).
In hypertension, a disturbance of O2
-
andNO balance may induce the generation
of oxidant and nitrating species, leading to
an enhancement of lipid peroxidation and
antioxidant consumption in plasma which
may result in disturbances ofNO bioactiv-
ity/bioavailability. In order to determine if
this free radical imbalance underlies endo-
thelial dysfunction and decreased NO bio-
availability in essential hypertension, we
evaluated flow-mediated endothelium-de-
pendent vasodilation, NO metabolites and
ChOx formation in hypertensive patients.
Material and Methods
Subjects
Hypertensive subjects (N = 11; age: 57.8
± 9.7 years, male/female: 4/7, blood pres-
sure: 148.3 ± 24.8/90.8 ± 10.2 mmHg) were
screened at the Kidney Hospital, Federal
University of São Paulo (UNIFESP), São
Paulo, SP, Brazil. Exclusion criteria included
myocardial infarction, unstable angina, smok-
ing, hyperlipidemia, diabetes, significant
valvular heart disease, use of antioxidant
vitamin supplements, and/or antihyperten-
sive therapy and estrogen replacement thera-
py. Normotensive subjects (N = 11; age:
48.4 ± 7.0 years, male/female: 3/8, blood
pressure: 119.4 ± 9.4/75.0 ± 8.0 mmHg)
were normal healthy volunteers with similar
exclusion criteria. The study was approved
by the Ethics Committee of UNIFESP. All
subjects signed written informed consent
forms and the study was conducted in accor-
dance to the principles of the Declaration of
Helsinki. Blood samples were collected into
EDTA-coated tubes and blood plasma was
immediately separated by low-speed cen-
trifugation (1500 g).
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Determination of nitrotyrosine in plasma
and LDL
Nitrotyrosine concentration of blood
plasma and LDL were determined by ELISA
(13). White 96-well plates were coated with
0.5 µg/ml nitro-BSA (100 µl/well) in 0.1 M
carbonate-bicarbonate buffer, pH 9.4, over-
night at 37ºC. Nitro-BSA was prepared ac-
cording to a published method (13) and final
nitrotyrosine concentration in nitro-BSA was
approximately 40-60 µM. 3-Nitrotyrosine in
the proteins of human plasma was deter-
mined by a competitive ELISA method (13).
After blocking with 5% nonfat dry milk for 2
h at 37ºC and washing with Tris-buffered
saline (TBS; 50 mM Tris-HCl, pH 7.4, and
150 mM NaCl) containing 0.6% Tween 20,
the plates were incubated with purified poly-
clonal anti-nitrotyrosine rabbit IgG (1:1000;
100 µl/well) and plasma (1:4 in TBS con-
taining 0.1% nonfat dry milk) or LDL (1 mg
of protein/ml), previously separated by gra-
dient ultracentrifugation for 2 h at 37ºC. The
nitro-BSA standard curve was obtained by
incubating serial dilutions of nitro-BSA (60
nM to 0.15 nM; 10 points) in TBS containing
0.1% nonfat dry milk (100 µl/well). Next,
the plates were washed and incubated with
mouse anti-rabbit IgG peroxidase conjugate
(1:5000; 100 µl/well) for 1 h at 37ºC, fol-
lowed by the addition of 2.3 mM luminol,
0.9 mM p-iodophenol (200 µl/well), and 3.9
nM hydrogen peroxide (50 µl/well). The
chemiluminescence intensity was determined
immediately using a microplate reader (Lumi-
Count, Packard, Meriden, CT, USA). The con-
centrations of free and protein-bound nitro-
tyrosine that inhibit anti-nitrotyrosine antibody
binding were estimated from the standard
curves and were reported as nitro-BSA equiva-
lents, i.e., an equivalent concentration of 3-
nitrotyrosine in nitro-BSA that produces the
equivalent inhibition as the nitrated proteins
(14). All samples and standard curves were
run in triplicate. Controls were performed by
preincubating the nitrated proteins with 10
mM sodium dithionite. Data for standard curves
were fitted to a logistic plot using the Origin
software. The nitro-BSA equivalents of plasma
samples were calculated by the logit plot on
the y-axis (logit (B/B0) = loge [B/B0]/[B - B/
B0] and log concentration on the x-axis.
Determination of nitrite, nitrate and
S-nitrosothiols
The concentration of nitrate in blood plasma
was determined by chemiluminescence, elic-
ited by the reaction of NO with ozone after
nitrate reduction with VCl3 saturated solution
in 1 M HCl, at 90ºC, using an NO analyzer
(NOATM280, Sievers Instruments Inc., Boul-
der, CO, USA). Nitrite was determined after
reduction with 1% KI solution in glacial acetic
acid to convert nitrite to NO. Samples used to
determine S-nitrosothiols were analyzed ei-
ther without pretreatment or after preincuba-
tion for 5 min at room temperature with a
molar excess of HgCl2 from a saturated aque-
ous solution, by the method of Ewing and
Janero (15). Samples containing 5 ml 1% KI
solution in glacial acetic acid were injected
into the NO analyzer according to the
manufacturer’s recommendations. For total S-
nitrosothiol quantification, the difference be-
tween the sample response after HgCl2 treat-
ment and without pretreatment was taken to
be the amount of S-nitrosothiol-bound NO.
Determination of cholesterol and
triglycerides
The concentrations of total cholesterol, tri-
glyceride and high density lipoprotein (HDL)-
cholesterol were determined by enzymatic
analyses using commercial kits (Biosystem,
Barcelona, Spain). LDL-cholesterol was cal-
culated by the Friedewald equation.
Determination of cholesterol oxides in LDL
LDL was isolated by sequential ultracen-
trifugation and ChOx content was determined
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by the method described by Hodis el al. (16).
The lipids were extracted with methanol:
chloroform (1:2) and applied to Diol solid-
phase extraction columns (Waters, São Paulo,
SP, Brazil). The cholesterol/ChOx were col-
lected, hydrolyzed by cold alkaline saponifi-
cation, derivatized with N,O-bis (trimethylsilyl)
trifluoroacetamide (BSTFA-Merck, São Paulo,
SP, Brazil), and analyzed by gas chromatogra-
phy. Gas chromatography was performed us-
ing a Hewlett Packard 6890 plus fitted with a
HP-5 capillary column (30 m x 0.32 mm ID,
0.25 µm film thickness - 5% phenylsiloxane,
Hewlett Packard, Hopkins, MN, USA) and
hydrogen as carrier gas.
Determination of antioxidants
The concentration of -tocopherol,
ß-carotene, lycopene (17), ascorbate and
urate (18) in blood plasma were determined
by HPLC using a C-18 ODS column (Shi-
madzu Corp., Tokyo, Japan).
Determination of plasma endothelin-1
The content of endothelin-1 in blood
plasma was determined by ELISA with a
commercially available reagent kit (EIAH
6901 - endothelin-1, Peninsula Laborato-
ries, Inc., Oxford, England).
Evaluation of endothelium-dependent
vasodilatation
Flow-mediated endothelium-dependent
vasodilatation of the brachial artery was de-
termined noninvasively with vascular ultra-
sound as previously described (19). Hyper-
emia was induced by a cuff that was inflated
on the proximal portion of the upper arm to
occlude arterial flow (>200 mmHg) for 5
min and rapidly deflated. Ultrasound images
of the brachial artery were obtained at base-
line and at 15 and 90 s after deflation. The
brachial artery was then allowed to return to
baseline level. Then, isosorbide dinitrate was
given sublingually, and the brachial artery
was imaged after 5 min. The response to
isosorbide dinitrate is a measure of endothe-
lium-independent vasodilatation. Intima-
media thickness was determined in the ca-
rotid and brachial arteries by ultrasound
(ATL, HDI-Ultramark-9).
Statistical analysis
Data are reported as means ± SEM. Sta-
tistical analysis was performed by the Tukey
test as a post-test after ANOVA, with P<0.05
considered to be significant. Correlations
were calculated by the Spearman test (Sigma
Stat software).
Results
Flow-mediated endothelium-dependent
vasodilatation in response to hyperemia was
61.1% lower in essential hypertensive pa-
tients (Figure 1); in contrast, the vasodilating
effect of sodium nitroprusside was similar in
normotensive subjects and hypertensive pa-
tients (results not shown). No difference was
found in the intima-medial thickness be-
tween the groups studied (normal: carotid
0.66 ± 0.08 mm, brachial 0.39 ± 0.19 mm;
hypertensive: carotid 0.75 ± 0.10 mm, bra-
chial 0.36 ± 0.08 mm). These findings sug-
gest impaired endothelial vasodilation in the
essential hypertensive subjects. The lack of
difference between the two groups in rela-
tion to the levels of nitrotyrosine, nitrite,
nitrate and S-nitrosothiols (Table 1) sug-
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Figure 1. Flow-mediated endo-
thelium-dependent vasodilation
in response to reactive hyper-
emia. Vasodilation was deter-
mined in the brachial artery at 10
and 90 s after cuff deflation. Re-
sults are reported as means ±
SEM of percent increase of di-
ameter. N = 11. *P<0.05 com-
pared to normotensive subjects
(Tukey test).
*
*
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gests that NO production is not decreased in
essential hypertension. The normal concen-
trations of cholesterol and triglycerides found
in hypertensive patients confirmed that they
had no associated hyperlipidemia (Table 1).
The increase of endothelin-1 in blood plasma
of hypertensive patients (Table 1) indicates
the importance of this contracting factor in
essential hypertension. The increased lipid
peroxidation in this situation is shown by the
higher content of 7-ketocholesterol (62%
higher in hypertensive than in normal sub-
jects), 5-cholestane-3ß,5,6ß-triol keto-
cholesterol (80% higher in hypertensive than
in normal subjects) and 5,6-epoxy-5-
cholestan-3-ol (50% higher in hyperten-
sive than in normal subjects) in LDL par-
ticles of hypertensive patients than in those
of normotensive subjects (Figure 2). The
increase of antioxidant consumption is indi-
cated by the lower concentrations of ß-caro-
tene, lycopene, ascorbate and urate in hyper-
tensive patients (Table 2). Correlation anal-
ysis showed that the flow-mediated endothe-
lium-dependent vasodilation was negatively
correlated with total cholesterol (r = 0.32,
P = 0.04) and positively correlated with -
tocopherol (r = 0.67, P<0.01), ascorbate (r =
0.44, P = 0.02) and urate (r = 0.41, P = 0.04).
Discussion
The present investigation showed reduced
flow-mediated endothelium-dependent va-
sodilation associated with increased levels
of LDL-cholesterol oxides and plasma endo-
thelin-1. This was accompanied by a de-
crease in lipid- and water-soluble antioxi-
dants in blood plasma of untreated patients
with borderline essential hypertension. Sev-
eral mechanisms implicating the action of
ox-LDL have been proposed to account for
the impairment of endothelium-dependent
vasodilation, such as i) reduced synthesis of
NO by endothelium in response to inhibi-
tion of NO synthase (NOS) (20), ii) NO
inactivation as a result of the increased pro-
Table 1. Lipids, endothelin-1, nitrotyrosine and nitric oxide derivatives in plasma of
patients with essential hypertension and normotensive subjects.
Analyte Normotensive Essential hypertensive
 (N =11) (N = 11)
Cholesterol (mg/dl) 166.7 ± 23.7 178.4 ± 11.4
VLDL-cholesterol (mg/dl) 24.2 ± 14.6 23.3 ± 12.5
LDL-cholesterol (mg/dl) 104.5 ± 35.3 111.5 ± 17.0
HDL-cholesterol (mg/dl) 38.8 ± 12.4 40.3 ± 15.7
Plasma nitrotyrosine (nitro ALB 40.2 ± 2.0 44.4 ± 2.2
equivalents) (nM)
LDL nitrotyrosine (nitro ALB 19.5 ± 6.9 18.6 ± 8.0
equivalents) (nM)
Nitrate (µM) 20.7 ± 16.0 18.3 ± 10.7
Nitrite (µM) 1.0 ± 0.5 1.0 ± 0.5
S-nitrosothiols (µM) 0.3 ± 0.2 0.3 ± 0.2
Endothelin-1 (ng/ml) 0.7 ± 0.1 0.9 ± 0.2*
Data are reported as means ± SEM. *P<0.05 compared to normotensive subjects
(Tukey test).
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Figure 2. Cholesterol oxides
(ChOx) in LDL of normotensive
subjects and essential hyper-
tensive patients. 1, 7-OH,
cholest-5-ene-3ß, 7-diol; 2, 7ß-
OH, cholest-5-ene-3ß, 7ß-diol;
3, cholesteryl-ß-epoxide, cho-
lestan-5ß, 6ß-epoxy-3ß-ol; 4,
cholesteryl--epoxide, choles-
tan-5, 6-epoxy-3ß-ol; 5, cho-
lestan-3ß, 5, 6ß-triol, and 6,
7-ketocholesterol. Results are
reported as means ± SEM.
N = 11. *P<0.05 compared to
the normotensive group (Tukey
test).
Table 2. Antioxidants in plasma of patients with essential hypertension and normoten-
sive subjects.
Analyte Normotensive Essential hypertensive
 (N =11) (N = 11)
Ascorbate (µM) 54.2 ± 24.9 29.2 ± 26.0*
Urate (µM) 156.4 ± 26.3 108.5 ± 18.9*
-Tocopherol (nmol/mg cholesterol) 23.9 ± 4.4 19.6 ± 5.6
ß-Carotene (nmol/mg cholesterol) 2.5 ± 1.2 1.1 ± 0.8*
Lycopene (nmol/mg cholesterol) 0.7 ± 0.2 0.4 ± 0.2*
Data are reported as means ± SEM. *P<0.05 compared to normotensive subjects
(Tukey test).
Normotensive
Hypertensive
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duction of O2
- resulting in peroxynitrite
(ONOO-) (21), iii) increased synthesis of
endothelin-1 (14), iv) inhibition of PGI2 re-
lease by endothelial cells (22), and v) selec-
tive inhibition of vascular smooth muscle
cell relaxation in rabbit and human arteries
(23). Moreover, ox-LDL potentiates the con-
tractile response of blood vessels to contrac-
tile agonists (11). Thus, ox-LDL not only
appears to inhibit the ability of blood vessels
to relax, but renders vessels more prone to
vasospasm in response to contractile stimuli
(11).
Among the components of ox-LDL, ChOx
are potent inhibitors of endothelium-depend-
ent relaxation in rabbit aortic segments (24).
Moreover, induction of hypertension by co-
arctation of the aorta in rabbits resulted in a
marked enhancement of ChOx in plasma
and aortic tissue (16). ChOx may be some of
the agents responsible for vascular injury or
inhibition of NO production by the vascular
endothelium. Cholesterol derivatives oxi-
dized at position 7, particularly 7-ketocho-
lesterol and 7ß-hydroxycholesterol, can sig-
nificantly reduce the histamine-induced re-
lease of NO from human umbilical vein
endothelial cells (10). It has been suggested
that 7-ketocholesterol does not reduce NO
release by altering the Ca2+-dependent NOS
activation steps, but rather by changing the
physicochemical properties of membranes
(10). A characteristic of endothelial NOS is
to be targeted to signal-transducing mem-
brane microdomains called plasmalemmal
caveolae. Membrane cholesterol is essential
for their normal function and oxidation of
cholesterol at position 7 may alter endotheli-
al NO production through direct effects on
caveolae (24). However, our data for hyper-
tensive patients did not indicate any effect
on NO production. Although 7-ketocholes-
terol was increased in the LDL of these
hypertensive patients, the values of NO me-
tabolites measured in plasma, i.e., nitrite,
nitrate and S-nitrosothiols, were similar to
those of normotensive subjects. 7-Ketocho-
lesterol and possibly other components of
ox-LDL have been reported to be assimi-
lated into glycosphingolipid-rich membranes
(associated with caveolae) and increase the
activity of src kinases, possibly by interact-
ing with caveolin (25). However, the in-
creases in plasma 7-ketocholesterol reported
in humans may be insufficient to affect NOS
association with caveolae and NO produc-
tion as found in cell culture.
It is known that in aqueous media, such
as blood plasma, NO reacts with oxygen to
yield nitrite (NO2
-), which is rapidly oxi-
dized to nitrate (NO3
-) (26). Moreover, per-
oxynitrite may undergo isomerization to form
nitrate (27). NO may also be converted to
the nitrosonium cation through interaction
with oxygen and thiol compounds (RSH;
28). S-nitrosothiols (RSNOs) are considered
to be NO pools, buffering the level of NO,
which is important for NO storage and trans-
port. Thus, these NO metabolites should
reflect the overall NO production in the
organism. One possible interpretation of our
data is that NO release may be decreased
only in the microenvironment of the
abluminal side of the endothelium at some
points of the vasculature causing impair-
ment of endothelium-dependent vasodila-
tion without affecting NO luminal release
or the circulating pool of NO metabolites. In
contrast to the lack of effect on NO metabo-
lites, the ChOx-enriched LDL particles may
act on endothelial cells enhancing endothe-
lin-1 release, which is a vasoconstrictive
molecule. In fact, we found increased con-
centrations of endothelin-1 in plasma of es-
sential hypertensive patients. Our data agree
with in vitro studies showing that ox-LDL
increases the release of endothelin-1 by en-
dothelial cells (14) or its activity on target
vascular cells. Indeed, ChOx have been
shown to alter the localization and activity of
the endothelin receptor by switching its in-
ternalization via caveolae to clathrin-coated
pits (29). It was recently reported that the
binding of activated platelets to the lectin-
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like ox-LDL receptor-1 (LOX-1) enhanced
the release of endothelin-1 from endothelial
cells (30). As LOX-1 is upregulated in vivo
in the presence of hypertension (31), ox-
LDL could modulate endothelin-1 release
through binding to LOX-1 in endothelial
cells. Although the ox-LDL components re-
sponsible for mediating endothelin-1 release
were not defined, ChOx are potential candi-
dates. This may be important for the patho-
physiology of essential hypertension and
deserves further studies.
The in vivo formation or origin of ChOx
is not completely understood. In vitro stud-
ies have shown that oxidation of cholesterol
in LDL occurs as a secondary event to lipid
peroxidation via the attack of fatty acid
peroxyl/alkoxyl radicals at the 7-position of
cholesterol (32). LDL oxidation by peroxy-
nitrite leads to similar cholesterol oxidation
(32). The main oxysterols formed were 5,6
ß-epoxycholesterol, 7-ketocholesterol, 7ß-
hydroxycholesterol, 7-hydroxycholesterol,
and 5,6 -epoxycholesterol (32). It is inter-
esting to note that in blood plasma (Figure 2)
the concentration of 5,6 ß-epoxycholesterol
is higher than that of 7-ketocholesterol, which
suggests that peroxynitrite may be one of the
oxidant species leading to in vivo free radi-
cal-mediated cholesterol oxidation. Patel et
al. (32) showed that no formation of 5-
cholestane-3ß,5,6ß-triol or the 24-,25-27-
hydroxycholesterols was detected in LDL
oxidized in vitro. However, in the plasma of
hypertensive patients studied here we found
increased levels of 7-ketocholesterol, 5,6-
epoxycholesterol and 5-cholestane-3ß,5,6ß-
triol. This profile is similar to that found in
hypertensive rabbits (16) and suggests that
additional mechanisms are contributing to in
vivo cholesterol oxidation.
The decreased superoxide dismutase ac-
tivity in blood plasma described for hyper-
tensive patients (33) would favor the reac-
tion of NO with O2
- resulting in peroxyni-
trite, or NO2 plus CO3
-, which would lead
to lipid peroxidation and nitration of pro-
teins. Pulse radiolysis studies have shown
that the highest nitration yield is obtained for
similar fluxes of O2
- and NO (34). Under
physiological conditions, NO (0.1-3.0 x 10-9
M) exceeds the estimated concentration of
O2
- (10-9-10-12 M), resulting in a high NO/
O2
- ratio in the vessel wall (35). In this
context, the effect of angiotensin II on endo-
thelium is particularly important during hy-
pertension. It is known that angiotensin II
increases systemic NO production and in-
duces the production of O2
- through AT1
receptor-dependent activation of the
NAD(P)H oxidase in endothelial cells (36).
Moreover, chronic AT1 blockade or angio-
tensin-converting enzyme inhibition prevents
the development of NOS inhibitor-induced
hypertension and reverses it by restoring
NO bioavailability and the endothelium-
dependent vasodilation (37). Although de-
creased scavenging of O2
- by superoxide
dismutase and increased destruction of NO
have been implicated in hypertension (38),
in the present study the nitrotyrosine levels
were not increased in plasma or LDL of
patients with essential hypertension. This
could be explained by the diffusion of per-
oxynitrite from the lumen of blood vessels to
the interior of blood cells. It is known that
peroxynitrite produced by the endothelium,
even in the presence of CO2, can diffuse and
penetrate the erythrocytes (39), possibly lead-
ing to the oxidation and/or nitration of the
protein and non-protein components of he-
moglobin. This diffusional property of per-
oxynitrite could explain the comparable
plasma levels of nitrotyrosine observed in
both normal and hypertensive patients. Thus,
the concentration of free and protein-associ-
ated nitrotyrosine in blood plasma is the net
product of the generation rate by intra- and
extracellular nitrating pathways.
In the present study, the flow-mediated
endothelium-dependent vasodilation was
positively correlated with the levels of -
tocopherol, ascorbate, and urate in essential
hypertensive patients. Additionally, the con-
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centrations of ascorbate, urate, ß-carotene,
and lycopene were lower in these patients in
comparison to normotensive subjects. Anti-
oxidants have positive effects in preserving
the biological activity of endothelium-
derived NO (12). Supplementation studies
have shown that ascorbate improves endo-
thelial dysfunction in patients with essential
hypertension (40). Moreover, in vitro stud-
ies have shown that ascorbate increases the
production of citrulline, the byproduct of
NO synthesis, and cyclic GMP, a marker of
NO bioactivity (12). Ascorbate may also
regenerate -tocopherol from its tocopher-
oxyl radical and sparing glutathione, which
could contribute to enhancing the formation
of S-nitrosothiols (12). It is suggested that -
tocopherol acts on the vascular wall by in-
hibiting protein kinase C activation by ox-
LDL, hence decreasing superoxide produc-
tion (12). Both ascorbate and -tocopherol
can reduce in vivo or ex vivo markers of
lipoprotein oxidation (12). Additionally,
treatment of hypertensive rabbits with the
antioxidant probucol reduced the increase of
ChOx content in plasma and aortic tissue
(16). Thus, the decrease of antioxidants could
contribute to the impairment of endotheli-
um-dependent vasodilation either by direct
effects on endothelium or by inhibiting the
generation of oxidized lipids, including
ChOx.
We have shown that individuals with
essential hypertension had reduced endothe-
lium-dependent vasodilation, in parallel to
increased ChOx levels and endothelin-1.
These increases are known to be associated
with oxidant stress and to be enhanced by the
decrease in plasma antioxidants, without al-
terations of NO-derived metabolites. To our
knowledge, ours is the first study to show an
increased formation of ChOx in hyperten-
sive humans, suggesting that ChOx may play
a role in the endothelial dysfunction found in
essential hypertension.
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